NO2015023I1 - Sekukinumab - Google Patents

Sekukinumab

Info

Publication number
NO2015023I1
NO2015023I1 NO2015023C NO2015023C NO2015023I1 NO 2015023 I1 NO2015023 I1 NO 2015023I1 NO 2015023 C NO2015023 C NO 2015023C NO 2015023 C NO2015023 C NO 2015023C NO 2015023 I1 NO2015023 I1 NO 2015023I1
Authority
NO
Norway
Prior art keywords
sekukinumab
Prior art date
Application number
NO2015023C
Other languages
English (en)
Other versions
NO2015023I2 (no
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32982602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2015023(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to NO2015023C priority Critical patent/NO2015023I1/no
Publication of NO2015023I2 publication Critical patent/NO2015023I2/no
Publication of NO2015023I1 publication Critical patent/NO2015023I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO2015023C 2004-08-05 2015-10-26 Sekukinumab NO2015023I1 (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO2015023C NO2015023I1 (no) 2004-08-05 2015-10-26 Sekukinumab

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0417487.6A GB0417487D0 (en) 2004-08-05 2004-08-05 Organic compound
PCT/EP2005/008470 WO2006013107A1 (en) 2004-08-05 2005-08-04 Il-17 antagonistic antibodies
NO2015023C NO2015023I1 (no) 2004-08-05 2015-10-26 Sekukinumab

Publications (2)

Publication Number Publication Date
NO2015023I2 NO2015023I2 (no) 2015-10-26
NO2015023I1 true NO2015023I1 (no) 2015-11-02

Family

ID=32982602

Family Applications (9)

Application Number Title Priority Date Filing Date
NO20070985A NO336279B1 (no) 2004-08-05 2007-02-20 IL-17 bindende antistoff, farmasøytisk sammensetning og kit omfattende slike antistoff, samt DNA konstruksjon som koder for slike IL-17 bindende antistoff og ekspresjonsvektor.
NO20150064A NO337286B1 (no) 2004-08-05 2015-01-13 IL-17 bindende antistoff for anvendelse ved behandling av ankyloserende spondylitt
NO20150065A NO337129B1 (no) 2004-08-05 2015-01-13 IL-17 bindende antistoff for anvendelse ved behandling av psoriasis artritt
NO2015023C NO2015023I1 (no) 2004-08-05 2015-10-26 Sekukinumab
NO20151787A NO341384B1 (no) 2004-08-05 2015-12-23 IL-17 bindende antistoff for anvendelse ved behandling av inflammatorisk artritt og anvendelse av det IL-17 bindende antistoff for fremstilling av medikament for behandling av ankyloserende spondylitt.
NO2016017C NO2016017I1 (no) 2004-08-05 2016-08-23 Sekukinumab
NO20171697A NO20171697A1 (no) 2004-08-05 2017-10-24 IL-17 Antagonistiske antistoffer
NO2018007C NO2018007I1 (no) 2004-08-05 2018-02-14 sekukinumab
NO2022026C NO2022026I1 (no) 2004-08-05 2022-06-24 Secukinumab - forlenget SPC

Family Applications Before (3)

Application Number Title Priority Date Filing Date
NO20070985A NO336279B1 (no) 2004-08-05 2007-02-20 IL-17 bindende antistoff, farmasøytisk sammensetning og kit omfattende slike antistoff, samt DNA konstruksjon som koder for slike IL-17 bindende antistoff og ekspresjonsvektor.
NO20150064A NO337286B1 (no) 2004-08-05 2015-01-13 IL-17 bindende antistoff for anvendelse ved behandling av ankyloserende spondylitt
NO20150065A NO337129B1 (no) 2004-08-05 2015-01-13 IL-17 bindende antistoff for anvendelse ved behandling av psoriasis artritt

Family Applications After (5)

Application Number Title Priority Date Filing Date
NO20151787A NO341384B1 (no) 2004-08-05 2015-12-23 IL-17 bindende antistoff for anvendelse ved behandling av inflammatorisk artritt og anvendelse av det IL-17 bindende antistoff for fremstilling av medikament for behandling av ankyloserende spondylitt.
NO2016017C NO2016017I1 (no) 2004-08-05 2016-08-23 Sekukinumab
NO20171697A NO20171697A1 (no) 2004-08-05 2017-10-24 IL-17 Antagonistiske antistoffer
NO2018007C NO2018007I1 (no) 2004-08-05 2018-02-14 sekukinumab
NO2022026C NO2022026I1 (no) 2004-08-05 2022-06-24 Secukinumab - forlenget SPC

Country Status (39)

Country Link
US (8) US7807155B2 (no)
EP (5) EP1776142B9 (no)
JP (1) JP4682200B2 (no)
KR (2) KR20080029018A (no)
CN (1) CN101001645B (no)
AR (1) AR050200A1 (no)
AT (1) ATE517924T1 (no)
AU (2) AU2005268857C1 (no)
BR (3) BRPI0513078C1 (no)
CA (1) CA2573586C (no)
CY (6) CY1111963T1 (no)
DK (4) DK2364729T6 (no)
EC (1) ECSP077198A (no)
ES (4) ES2367440T7 (no)
FR (1) FR15C0048I2 (no)
GB (1) GB0417487D0 (no)
HK (3) HK1101277A1 (no)
HR (3) HRP20110758T4 (no)
HU (4) HUE025815T2 (no)
IL (1) IL180717A (no)
LT (3) LT2902039T (no)
LU (2) LU92768I2 (no)
MA (1) MA28982B1 (no)
MX (1) MX2007001338A (no)
MY (1) MY144925A (no)
NL (1) NL300749I2 (no)
NO (9) NO336279B1 (no)
NZ (1) NZ552658A (no)
PE (1) PE20060418A1 (no)
PL (4) PL1776142T4 (no)
PT (4) PT2902039T (no)
RU (2) RU2426741C3 (no)
SG (1) SG155186A1 (no)
SI (4) SI2364729T1 (no)
TN (1) TNSN07034A1 (no)
TR (1) TR201808057T4 (no)
TW (1) TWI359153B (no)
WO (1) WO2006013107A1 (no)
ZA (1) ZA200700242B (no)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP1933869B1 (en) * 2005-09-01 2009-10-14 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
EP2481753B1 (en) * 2005-12-13 2018-04-18 Eli Lilly and Company Anti-IL-17 Antibodies
RS52860B (en) 2005-12-20 2013-12-31 Sbi Biotech Co. Ltd. ANTI-ILT7 ANTITELO
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
RU2430110C2 (ru) 2006-01-31 2011-09-27 Новартис Аг Антитела - антагонисты интерлейкина-17 (ил-17) для лечения рака
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
WO2008021156A2 (en) * 2006-08-11 2008-02-21 Schering Corporation Antibodies to il-17a
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
EP2417974A1 (en) 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
KR102606597B1 (ko) 2007-05-29 2023-11-29 노파르티스 아게 항-ｉｌ-1-베타 치료법에 대한 신규 적응증
AU2008266745B2 (en) * 2007-06-20 2014-04-17 Merck Sharp & Dohme Corp. Joint destruction biomarkers for anti-IL-17A therapy of inflammatory joint disease
WO2009015063A2 (en) * 2007-07-23 2009-01-29 Centocor Methods and compositions for treating fibrosis related disorders using il-17 antagonists
US20110195509A1 (en) * 2007-09-06 2011-08-11 Drew Pardoll Treatment of th17-mediated autoimmune disease via inhibition of stat 3
WO2009072802A2 (en) * 2007-12-03 2009-06-11 Amorepacific Corporation Composition for slimming
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CA3069576A1 (en) * 2008-01-09 2009-07-16 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
US9029508B2 (en) 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP2279001B1 (en) * 2008-04-29 2015-09-30 Amgen Research (Munich) GmbH Inhibitors of gm-csf and il-17 for therapy
US20090317400A1 (en) 2008-05-05 2009-12-24 Krzysztof Masternak Anti-IL 17A/IL-17F Cross-Reactive Antibodies and Methods of Use Thereof
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
AU2009296299A1 (en) 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human IL 17 and uses thereof
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
NO2424895T3 (no) * 2009-04-27 2018-02-03
PE20120815A1 (es) 2009-05-05 2012-07-08 Novimmune Sa Anticuerpos anti il-17f y metodos de uso de los mismos
NZ598929A (en) 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
KR20120093932A (ko) * 2009-10-10 2012-08-23 일레븐 바이오테라피틱스, 아이엔씨. Ｉｌ－１７ 패밀리 사이토카인 조성물들 및 용도들
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2493506B1 (en) 2009-10-30 2019-04-10 Janssen Biotech, Inc. Il-17a antagonists
KR20130080790A (ko) 2010-05-20 2013-07-15 아블린쓰 엔.브이. Ｈｅｒ３와 관련된 생물학적 물질들
MY160445A (en) 2010-08-03 2017-03-15 Abbvie Inc Dual Variable Domain Immunoglobulins And Uses Thereof
WO2012018767A2 (en) 2010-08-05 2012-02-09 Anaptysbio, Inc. Antibodies directed against il-17
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
EP4137514A1 (en) 2010-10-08 2023-02-22 Novartis AG Methods of treating psoriasis using il-17 antagonists
AU2014259523B2 (en) * 2010-11-05 2016-02-04 Novartis Ag Methods of treating psoriatic arthritis using IL-17 antagonists
CN104800844A (zh) 2010-11-05 2015-07-29 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法
WO2012082573A1 (en) 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
JP5947041B2 (ja) * 2011-01-07 2016-07-06 第一三共ヘルスケア株式会社 安全なｉｌ−１７産生抑制剤
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
US20140004540A1 (en) * 2011-01-13 2014-01-02 Universite Paris Descartes Methods and kits for predicting the risk of having a cardiovascular event in a subject
CA2823812C (en) 2011-01-14 2017-02-14 Ucb Pharma S.A. Antibody molecules which bind il-17a and il-17f
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
CN107915769A (zh) 2011-03-29 2018-04-17 葛兰素史密斯克莱有限责任公司 用于蛋白纯化的缓冲液体系
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
JP2015504430A (ja) * 2011-11-21 2015-02-12 ノバルティス アーゲー Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9580501B2 (en) 2011-12-16 2017-02-28 Synthon Biopharmaceuticals B.V. Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
EP2797955A2 (en) 2011-12-30 2014-11-05 AbbVie Inc. Dual variable domain immunoglobulins against il-13 and/or il-17
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
KR101674784B1 (ko) 2012-04-05 2016-11-09 에프. 호프만-라 로슈 아게 인간 tweak 및 인간 il17에 대한 이중특이적 항체 및 이의 용도
KR20150010709A (ko) 2012-04-20 2015-01-28 노파르티스 아게 Il-17 길항제를 사용하는 강직성 척추염의 치료 방법
SI2852615T1 (sl) 2012-05-22 2019-02-28 Bristol-Myers Squibb Company IL-17A/F IL-23 bispecifična protitelesa in njihova uporaba
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
KR20210111353A (ko) 2012-11-01 2021-09-10 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
EP4074834A1 (en) 2012-11-26 2022-10-19 ModernaTX, Inc. Terminally modified rna
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
SG11201505330QA (en) 2013-02-08 2015-08-28 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
WO2014155278A2 (en) * 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
US10434172B2 (en) 2013-08-15 2019-10-08 Novartis Ag Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists
WO2015028657A1 (en) 2013-08-30 2015-03-05 Takeda Gmbh Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
EP3072905B1 (en) * 2013-11-18 2020-08-19 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-17a binding agent and uses thereof
CN105916883B (zh) * 2014-01-28 2019-12-03 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
EP3191120B1 (en) 2014-09-10 2024-04-10 Novartis Ag Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
BR112017007379A2 (pt) 2014-10-14 2017-12-19 Dana Farber Cancer Inst Inc moléculas de anticorpo para pd-l1 e usos das mesmas
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
BR112017014559A2 (pt) 2015-01-12 2018-05-15 Affibody Ab polipeptídeo de ligação de il-17a, proteína de fusão ou conjugado, complexo, polinucleotídeo que codifica um polipeptídeo, e, composição
EP3250927B1 (en) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis
CN105315371B (zh) * 2015-03-05 2018-05-29 北京百特美博生物科技有限公司 抗人il-17单克隆抗体
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US20180201673A1 (en) 2015-07-16 2018-07-19 Eli Lilly And Company Treatment of pruritus
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3365011A1 (en) 2015-10-19 2018-08-29 Novartis AG Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
MX2018010771A (es) 2016-03-10 2019-05-15 Viela Bio Inc Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
EP3426680A4 (en) 2016-03-10 2020-03-11 Acceleron Pharma Inc. TYPE 2 ACTIVIN RECEPTOR BINDING PROTEINS AND USES THEREOF
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
FR3051673B1 (fr) * 2016-05-24 2018-06-22 Assistance Publique - Hopitaux De Paris Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
US20190194311A1 (en) 2016-07-19 2019-06-27 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
ES2905917T3 (es) 2016-09-14 2022-04-12 Beijing Hanmi Pharmaceutical Co Ltd Anticuerpo que se une específicamente a IL-17A y fragmento funcional del mismo
WO2018096467A1 (en) 2016-11-28 2018-05-31 Novartis Ag Methods of treating acne using interleukin-17 (il-17) antagonists
WO2018148585A1 (en) 2017-02-10 2018-08-16 Genentech, Inc. Anti-tryptase antibodies, compositions thereof, and uses thereof
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
TW201842933A (zh) 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
CN108359011B (zh) 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
CN111344043A (zh) 2017-11-02 2020-06-26 诺华股份有限公司 使用白细胞介素-17(il-17)拮抗剂治疗肌腱病的方法
US20200277369A1 (en) * 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
TW201925782A (zh) 2017-11-30 2019-07-01 瑞士商諾華公司 靶向bcma之嵌合抗原受體及其用途
CN112203685A (zh) * 2018-03-29 2021-01-08 瑞美德生物医药科技有限公司 使用结合白细胞介素-17a(il-17a)的抗体的自身免疫紊乱和炎性紊乱的治疗
JP7398396B2 (ja) 2018-06-01 2023-12-14 ノバルティス アーゲー Ｂｃｍａに対する結合分子及びその使用
WO2020024931A1 (en) * 2018-07-31 2020-02-06 Shen Weiqun Anti-il-17a antibodies and use thereof
EP3856772A1 (en) 2018-09-25 2021-08-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
CN113631574A (zh) 2019-01-31 2021-11-09 努玛治疗有限公司 对TNFα和IL-17A具有特异性的多特异性抗体、靶向IL-17A的抗体及其使用方法
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
EP3976032A4 (en) * 2019-05-31 2023-06-14 Figene, LLC SIMULTANEOUS ACTIVATION OF REGENERATIVE AND TOLEROGENIC PROCESSES BY COMPOSITIONS BASED ON FIBROBLASTS IN THE TREATMENT OF MULTIPLE SCLEROSIS
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
CN114286827B (zh) 2019-07-26 2024-01-12 神州细胞工程有限公司 人源化抗il17a抗体及其应用
WO2021018191A1 (zh) 2019-07-30 2021-02-04 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
KR20220066318A (ko) 2019-09-20 2022-05-24 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용한 자가면역 질환의 치료 방법
EP4042167A1 (en) 2019-09-30 2022-08-17 Janssen Pharmaceutica NV Compositions and methods for an il-17 target engagement assay with large molecule modulators
US20230009657A1 (en) 2019-11-19 2023-01-12 Novartis Ag Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
IL293354A (en) 2019-12-06 2022-07-01 Novartis Ag Methods for treating flatulence using interleukin-17 (il-17) antagonists
CN114805577B (zh) * 2019-12-31 2023-11-21 南京融捷康生物科技有限公司 针对il-17ra蛋白的抗体及其制备方法和应用
BR112022026273A2 (pt) 2020-06-23 2023-01-17 Novartis Ag Métodos de tratamento da doença ocular da tireoide e orbitopatia de graves usando antagonistas de interleucina-17 (il-17)
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
EP4255927A1 (en) 2020-12-02 2023-10-11 Fresenius Kabi Deutschland GmbH Methods of selectively reducing antibodies
CN116635416A (zh) 2020-12-22 2023-08-22 诺华股份有限公司 用于在细胞培养期间降低分泌的重组表达蛋白质中半胱氨酸残基的氧化水平的方法
WO2023209519A1 (en) 2022-04-25 2023-11-02 Novartis Ag Crystalline forms of an il-17 inhibitor
WO2023223211A1 (en) 2022-05-16 2023-11-23 Novartis Ag Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
WO2023223263A1 (en) 2022-05-18 2023-11-23 Novartis Ag Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
CN117843778A (zh) * 2023-12-21 2024-04-09 北京贝来药业有限公司 针对白介素家族成员的新型纳米抗体及其产品和应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US5869286A (en) 1995-03-23 1999-02-09 Immunex Corporation Receptor that binds IL-17
AU727480B2 (en) * 1995-07-19 2000-12-14 Genetics Institute, Llc Human CTLA-8 and uses of CTLA-8-related proteins
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
ES2181915T3 (es) 1995-10-27 2003-03-01 Schering Corp Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.
ES2326347T3 (es) 1996-11-27 2009-10-07 Immunex Corporation Metodo para regular la produccion de oxido nitrico.
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
ES2333385T3 (es) 1997-09-17 2010-02-19 Human Genome Sciences, Inc. Proteina del tipo de interleuquina-17.
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
JP4620243B2 (ja) 1997-11-10 2011-01-26 サイティミューン サイエンシーズ， インコーポレイテッド 生物学的に活性な因子の標的化された送達のための組成物および方法
US6562578B1 (en) * 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
AU2004799A (en) 1997-12-19 1999-07-12 Millennium Biotherapeutics, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
EP1045905A2 (en) 1998-01-09 2000-10-25 Immunex Corporation Il-17rh dna and polypeptides
WO1999035267A1 (en) 1998-01-09 1999-07-15 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
AU3291099A (en) 1998-02-11 1999-08-30 Maxygen, Inc. Genetic vaccine vector engineering
DK1076703T4 (da) 1998-05-15 2011-03-28 Genentech Inc Terapeutiske anvendelser af IL-17-homologe polypeptider
CA2706859A1 (en) 1998-09-17 2000-03-23 Zymogenetics, Inc. Mammalian transforming growth factor beta - 9
WO2000020593A1 (en) 1998-10-02 2000-04-13 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
DE29820466U1 (de) 1998-11-16 1999-04-08 Reutter, Werner, Prof. Dr.med., 14195 Berlin Rekombinante Glycoproteine und sie enthaltende Arzneimittel
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
EP1895006B1 (en) 1999-01-11 2011-11-02 Schering Corporation Interleukin-17 related mammalian cytokines. Polynucleotides encoding them. Uses
AU3207000A (en) 1999-01-11 2000-08-01 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
ES2173678T3 (es) 1999-01-27 2002-10-16 Idea Ag Vacunacion no invasiva a traves de la piel.
HU229520B1 (en) 1999-02-12 2014-01-28 Scripps Research Inst Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US6036128A (en) 1999-05-17 2000-03-14 Common Ground Recycling, Inc. Tire shredding machine and method of using the same
EP1053751A1 (en) 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
WO2001015728A1 (en) 1999-08-27 2001-03-08 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
JP2001086046A (ja) * 1999-09-09 2001-03-30 Nec Corp カメラ付き携帯電話装置
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
EP2281843B1 (en) 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
WO2002033083A2 (en) 2000-10-13 2002-04-25 Eli Lilly And Company Methods of using a human il-17-related polypeptide to treat disease
MXPA03003407A (es) * 2000-10-18 2004-05-04 Immunex Corp Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.
AU2002326285A1 (en) 2001-01-25 2003-01-02 Zymogenetics, Inc. Method for treating psoriasis by using an il-17d antagonist
CA2658221C (en) * 2001-04-27 2012-11-27 Kyowa Hakko Kirin Co., Ltd. Anti-cd40 monoclonal antibody
CA2467521A1 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
US7456264B2 (en) * 2003-05-21 2008-11-25 Medarex, Inc. Human monoclonal antibodies against Bacillus anthracis protective antigen
EP1983000B1 (en) 2003-11-21 2015-09-02 UCB Biopharma SPRL Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
BRPI0510617A (pt) 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP1933869B1 (en) 2005-09-01 2009-10-14 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease

Also Published As

Publication number Publication date
NO337286B1 (no) 2016-02-29
PL1776142T6 (pl) 2016-06-30
PT2364729E (pt) 2014-09-01
NO2022026I1 (no) 2022-06-24
RU2007108067A (ru) 2008-09-10
ECSP077198A (es) 2007-02-28
ZA200700242B (en) 2008-08-27
HRP20181069T1 (hr) 2018-09-07
AU2005268857A1 (en) 2006-02-09
EP2364729A3 (en) 2012-01-18
LUC00088I2 (no) 2018-12-17
EP2902039A1 (en) 2015-08-05
PL2364729T6 (pl) 2016-06-30
PT1776142E (pt) 2011-10-06
BR122017009404B1 (pt) 2022-02-22
US20230235038A1 (en) 2023-07-27
BRPI0513078A (pt) 2008-04-22
AU2010201689A1 (en) 2010-05-20
CY2018027I2 (el) 2020-05-29
DK1776142T3 (da) 2011-10-31
HRP20110758T4 (hr) 2015-07-31
GB0417487D0 (en) 2004-09-08
CY2015030I1 (el) 2015-11-04
BRPI0513078C1 (pt) 2021-05-25
US8617552B2 (en) 2013-12-31
PL2364729T3 (pl) 2014-10-31
SI2366405T1 (sl) 2015-07-31
CY1116256T1 (el) 2017-02-08
ES2367440T3 (es) 2011-11-03
HK1256639A1 (zh) 2019-09-27
RU2011113153A (ru) 2012-10-20
LTPA2015029I1 (lt) 2022-07-11
US20190270804A1 (en) 2019-09-05
TNSN07034A1 (en) 2008-06-02
JP2008507988A (ja) 2008-03-21
EP1776142B1 (en) 2011-07-27
EP2366405A2 (en) 2011-09-21
DK2366405T3 (en) 2015-05-11
AU2005268857B8 (en) 2010-05-27
CY1115444T1 (el) 2017-01-04
HUE038187T2 (hu) 2018-10-29
LTPA2018515I1 (lt) 2018-10-25
ES2677245T3 (es) 2018-07-31
TR201808057T4 (tr) 2018-06-21
HK1101277A1 (en) 2007-10-12
EP2902039B1 (en) 2018-04-11
SI2364729T1 (sl) 2014-08-29
BRPI0513078B1 (pt) 2019-02-19
CY2018027I1 (el) 2020-05-29
DK2364729T3 (da) 2014-07-21
HK1207559A1 (en) 2016-02-05
NO20150065L (no) 2007-03-30
NO337129B1 (no) 2016-01-25
SI2902039T1 (en) 2018-07-31
CN101001645A (zh) 2007-07-18
HUS1800040I1 (hu) 2018-11-28
ES2367440T9 (es) 2021-04-28
ES2536228T3 (es) 2015-05-21
NO341384B1 (no) 2017-10-30
HUE025815T2 (en) 2016-04-28
SG155186A1 (en) 2009-09-30
CY2015030I2 (el) 2017-11-14
BR122018075556B1 (pt) 2022-10-18
AU2005268857B2 (en) 2010-01-28
MX2007001338A (es) 2008-03-11
DK2902039T3 (en) 2018-07-16
CN101001645B (zh) 2012-09-05
ES2487533T3 (es) 2014-08-21
CY1120723T1 (el) 2019-12-11
EP2364729B3 (en) 2015-06-24
NO2016017I1 (no) 2016-08-23
PL2902039T3 (pl) 2018-09-28
NO20171697A1 (no) 2007-03-30
TWI359153B (en) 2012-03-01
SI1776142T1 (sl) 2011-11-30
ES2367440T7 (es) 2015-07-14
EP3409288A1 (en) 2018-12-05
IL180717A0 (en) 2007-06-03
MA28982B1 (fr) 2007-11-01
TW200617025A (en) 2006-06-01
EP1776142B9 (en) 2016-09-07
KR100852523B1 (ko) 2008-08-14
CA2573586A1 (en) 2006-02-09
KR20080029018A (ko) 2008-04-02
LTC1776142I2 (lt) 2022-07-11
DK2364729T6 (en) 2015-07-06
HRP20150480T1 (hr) 2015-07-17
CA2573586C (en) 2013-06-25
NO20070985L (no) 2007-03-30
EP2364729A2 (en) 2011-09-14
DK1776142T6 (en) 2015-07-06
EP2366405B1 (en) 2015-02-25
US20090280131A1 (en) 2009-11-12
LU92768I2 (fr) 2015-11-03
PL1776142T4 (pl) 2018-04-30
CY1111963T1 (el) 2015-11-04
AR050200A1 (es) 2006-10-04
PL2366405T3 (pl) 2015-08-31
FR15C0048I2 (fr) 2015-11-20
PE20060418A1 (es) 2006-06-15
WO2006013107A1 (en) 2006-02-09
NO336279B1 (no) 2015-07-06
JP4682200B2 (ja) 2011-05-11
PT2902039T (pt) 2018-07-17
NO2015023I2 (no) 2015-10-26
US8119131B2 (en) 2012-02-21
PL1776142T3 (pl) 2011-12-30
HRP20110758T1 (en) 2011-11-30
US20140079719A1 (en) 2014-03-20
US20120107325A1 (en) 2012-05-03
RU2426741C3 (ru) 2017-11-15
NO20151787L (no) 2006-02-06
US20150152178A1 (en) 2015-06-04
US20170355762A1 (en) 2017-12-14
FR15C0048I1 (fr) 2015-08-28
US9765140B2 (en) 2017-09-19
EP1776142B3 (en) 2015-06-24
BRPI0513078B8 (pt) 2019-08-27
HUS1500037I1 (hu) 2017-10-30
RU2426741C2 (ru) 2011-08-20
ES2487533T7 (es) 2015-07-14
US20100215666A1 (en) 2010-08-26
AU2005268857C1 (en) 2012-01-19
NL300749I2 (nl) 2017-11-02
LT2902039T (lt) 2018-06-25
US10344084B2 (en) 2019-07-09
EP1776142A1 (en) 2007-04-25
MY144925A (en) 2011-11-30
EP2364729B1 (en) 2014-05-14
ATE517924T1 (de) 2011-08-15
IL180717A (en) 2012-07-31
NO20150064L (no) 2007-03-30
KR20070036166A (ko) 2007-04-02
PT2366405E (pt) 2015-06-30
AU2010201689B2 (en) 2011-09-29
NZ552658A (en) 2009-11-27
EP2366405A3 (en) 2012-01-18
US7807155B2 (en) 2010-10-05
NO2018007I1 (no) 2018-02-14

Similar Documents

Publication Publication Date Title
CY2019034I2 (el) 4-φαινυλαμινο-κιναζολιν-6-υλ-αμιδια
NO2018007I1 (no) sekukinumab
DE502005005035D1 (de) Wischblatt
DE112005001624A5 (de) Brillengestell
ATE520680T1 (de) Hiv-hemmende 5-heterocyclylpyrimidine
ATE392425T1 (de) Thiazolyl-dihydro-indazole
ATE459633T1 (de) Makrolide
DE502005004843D1 (de) Einspritzventil
DE502005006395D1 (de) Verschlusskappe
DE502005005991D1 (de) Sensorleuchte
DE502005004842D1 (de) Wischblatt
DE112005000809A5 (de) Wankstabilisierungseinrichtung
DE502005008587D1 (de) Kugelgelenk
DE502005007739D1 (de) Kranballastierungssystem
DE502005007584D1 (de) Raftfahrzeuge
DE502005002602D1 (de) Fahrzeugtemperiersystem
DE502005004695D1 (de) Sicherheitsfangseil
DE502004012213D1 (de) Flachdichtung
DE502005007997D1 (de) Aftfahrzeug
AT500198B8 (de) Ladewagen
DE202004017327U1 (de) Fitnessrad
ATE389633T1 (de) Omega-phenyloctanamide
DE112005000794T5 (de) Urethanspritzpistolenanordnung
DE502005007686D1 (de) Gutverteileinrichtung
DE502005004160D1 (de) Seitenblinkleuchte

Legal Events

Date Code Title Description
MK1K Patent expired